Please assess the completion status of the following clinical trial:

Trial Title: Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus as per American Diabetes Association guidelines~* On metformin monotherapy (\>=1500 mg/day) for \>=8 weeks with a Visit 1/Screening A1C \>=7.5% and \<=11.0% (\>=58 mmol/mol and \<=97 mmol/mol) OR On metformin monotherapy (\>=1500 mg/day) for \<8 weeks with a Visit 1/Screening A1C \>=7.5% and \<=11.0% (\>=58 mmol/mol and \<=97 mmol/mol) OR On metformin monotherapy \<1500 mg/day with a Visit 1/Screening A1C \>=8.0% and \<=11.5% (\>=64 mmol/mol and \<=102 mmol/mol)~* Body mass index (BMI) \>=18.0 kg/m\^2~* Male or female not of reproductive potential~* Female of reproductive potential who agrees to remain abstinent from heterosexual activity or to use 2 acceptable combinations of contraception~Exclusion Criteria:~* History of type 1 diabetes mellitus or ketoacidosis~* History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant~* A known hypersensitivity or intolerance to any sodium glucose co-transporter 2 (SGLT2) inhibitor or sitagliptin~* Has been treated with any of the following agents within 12 weeks of study start or during the pre-randomization period: Insulin of any type (except for short-term use \[i.e., \<=7 days\] during concomitant illness or other stress), other injectable anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), pioglitazone or rosiglitazone, other SGLT2 inhibitors, alpha glucosidase inhibitors or meglitinides, dipeptidyl-peptidase 4 inhibitor (DPP-4 inhibitor), sulfonylureas (SUs), bromocriptine (Cycloset™), colesevelam (Welchol™), any other antihyperglycemic agents (AHA) with the exception of the protocol-approved agents~* Is on a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable prior to study start~* Has undergone bariatric surgery within the past 12 months or \>12 months and is not weight stable prior to study start~* A history of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study start~* Active, obstructive uropathy or indwelling urinary catheter~* History of malignancy \<=5 years prior to study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer~* A known history of human immunodeficiency virus (HIV)~* A blood dyscrasia or any disorder causing hemolysis or unstable red blood cells, or a clinically important hematological disorder (e.g. aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)~* A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease~* Any clinically significant malabsorption condition~* Current treatment for hyperthyroidism~* On thyroid replacement therapy and not on a stable dose for at least 6 weeks prior study start~* On a previous clinical study with ertugliflozin~* Estimated glomerular filtration rate (eGFR) (using the 4-variable Modification of Diet in Renal Disease Study Equation (MDRD) equation) \<60 mL/min/1.73 m\^2~* Serum creatinine \>= 1.3 mg/dL (115 µmol/L) for males and \>= 1.2 mg/dL (106 µmol/L) for females~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2 times upper limit of normal~* Hemoglobin \<12 g/dL (120 g/L) for males and \<11 g/dL (110 g/L) for females.~* Participated in other studies involving investigational drug(s) 30 days prior to study start~* Surgical procedure within 6 weeks prior to study start or major surgery planned during the trial~* Positive urine pregnancy test~* Pregnant or breast-feeding, or planning to conceive during the trial, including 14 days following the last dose of study medication~* Planning to undergo hormonal therapy in preparation for egg donation during the trial, including 14 days following the last dose of study medication~* Routinely consumes \>2 alcoholic drinks per day or \>14 alcoholic drinks per week or engages in binge drinking~* Donated blood or blood products within 6 weeks of study start

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ertugliflozin 5 mg + sitagliptin 100 mg (Type: EXPERIMENTAL): Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
- Ertugliflozin 15 mg + sitagliptin 100 mg (Type: EXPERIMENTAL): Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
- Ertugliflozin 5 mg (Type: EXPERIMENTAL): Ertugliflozin 5 mg, oral, once daily for 52 weeks
- Ertugliflozin 15 mg (Type: EXPERIMENTAL): Ertugliflozin, oral, once daily for 52 weeks
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): Sitagliptin 100 mg, oral, once daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete